Norbert Galldiks

List of Publications by Year in Descending Order

213 papers	7,061 citations	44 h-index	77 g-index
232 ext. papers	8,765 ext. citations	4.3 avg, IF	5.93 L-index

#	Paper	IF	Citations
213	Use of advanced neuroimaging and artificial intelligence in meningiomas.. *Brain Pathology*, **2022**, 32, e13015	6	1
212	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**,	8.8	2
211	Early Treatment Response Assessment Using F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. *Journal of Nuclear Medicine*, **2021**, 62, 918-925	8.9	8
210	Radiomics outperforms semantic features for prediction of response to stereotactic radiosurgery in brain metastases. *Radiotherapy and Oncology*, **2021**, 166, 37-43	5.3	0
209	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. *Neuro-Oncology*, **2021**, 23, vi126-vi127	1	0
208	NIMG-27. REGORAFENIB RESPONSE ASSESSMENT USING FET PET IN PATIENTS WITH PROGRESSIVE GLIOMA. *Neuro-Oncology*, **2021**, 23, vi134-vi134	1	
207	Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET. *Frontiers in Oncology*, **2021**, 11, 735388	5.3	
206	NIMG-06. CHARACTERIZATION OF LONG-TERM METABOLIC CHANGES OF IRRADIATED BRAIN METASTASES USING SERIAL DYNAMIC FET PET IMAGING. *Neuro-Oncology*, **2021**, 23, vi128-vi128	1	
205	NIMG-20. DIFFERENTIATION OF TREATMENT-RELATED CHANGES FROM TUMOR PROGRESSION FOLLOWING BRACHYTHERAPY IN PATIENTS WITH WHO II AND III GLIOMAS USING FET PET. *Neuro-Oncology*, **2021**, 23, vi132-vi132	1	
204	Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. *Scientific Reports*, **2021**, 11, 20828	4.9	0
203	Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value: A Multicentric 11C-Methionine and 18F-FDOPA PET Experience. *Clinical Nuclear Medicine*, **2021**, 46, e36-e37	1.7	4
202	Use of PET Imaging in Neuro-Oncological Surgery. *Cancers*, **2021**, 13,	6.6	11
201	Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. *Clinical Cancer Research*, **2021**, 27, 3704-3713	12.9	3
200	Loss of H3K27me3 in meningiomas. *Neuro-Oncology*, **2021**, 23, 1282-1291	1	7
199	Lesion-Function Analysis from Multimodal Imaging and Normative Brain Atlases for Prediction of Cognitive Deficits in Glioma Patients. *Cancers*, **2021**, 13,	6.6	1
198	Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation. *Neuro-Oncology*, **2021**, 23, 1410-1411	1	1
197	Radiomics in neuro-oncology: Basics, workflow, and applications. *Methods*, **2021**, 188, 112-121	4.6	38

196	Current trends in the use of O-(2-[F]fluoroethyl)-L-tyrosine ([F]FET) in neurooncology. *Nuclear Medicine and Biology*, **2021**, 92, 78-84	2.1	11
195	Sequential implementation of DSC-MR perfusion and dynamic [F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1956-1965	8.8	6
194	Treatment Monitoring of Immunotherapy and Targeted Therapy Using F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. *Journal of Nuclear Medicine*, **2021**, 62, 464-470	8.9	10
193	Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?. *Current Treatment Options in Neurology*, **2021**, 23, 1	4.4	
192	Combined F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: differentiation of true progression from treatment-related changes. *Neuro-Oncology Advances*, **2021**, 3, vdab044	0.9	1
191	A Linearized Fit Model for Robust Shape Parameterization of FET-PET TACs. *IEEE Transactions on Medical Imaging*, **2021**, 40, 1852-1862	11.7	0
190	Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients. *Cancers*, **2021**, 13,	6.6	4
189	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. *Neuro-Oncology*, **2021**, 23, 881-893	1	23
188	F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. *Journal of Neuro-Oncology*, **2021**, 155, 71-80	4.8	2
187	Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.. *Neuro-Oncology*, **2021**,	1	4
186	Applications of radiomics and machine learning for radiotherapy of malignant brain tumors. *Strahlentherapie Und Onkologie*, **2020**, 196, 856-867	4.3	21
185	MRI Follow-up of Astrocytoma: Automated Coregistration and Color-Coding of FLAIR Sequences Improves Diagnostic Accuracy With Comparable Reading Time. *Journal of Magnetic Resonance Imaging*, **2020**, 52, 1197-1206	5.6	1
184	Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment. *NeuroImage: Clinical*, **2020**, 27, 102287	5.3	8
183	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. *Molecules*, **2020**, 25,	4.8	15
182	PET/MRI Radiomics in Patients With Brain Metastases. *Frontiers in Neurology*, **2020**, 11, 1	4.1	77
181	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[F]-fluoroethyl)-L-tyrosine PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 1486-1495	8.8	9
180	Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. *Case Reports in Oncology*, **2020**, 13, 35-42	1	3
179	Flare Phenomenon in -(2-F-Fluoroethyl)-l-Tyrosine PET After Resection of Gliomas. *Journal of Nuclear Medicine*, **2020**, 61, 1294-1299	8.9	5

178   NIMG-26. DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET. *Neuro-Oncology*, **2020**, 22, ii152-ii153   1

177   NIMG-14. MACHINE LEARNING-BASED EVALUATION OF STATIC AND DYNAMIC FET-PET FOR THE DETECTION OF PSEUDOPROGRESSION IN PATIENTS WITH IDH-WILDTYPE GLIOBLASTOMA. *Neuro-Oncology*, **2020**, 22, ii149-ii150   1

176   NIMG-43. IMAGING FINDINGS FOLLOWING REGORAFENIB IN PATIENTS WITH MALIGNANT GLIOMA: FET PET ADDS VALUABLE INFORMATION TO ANATOMICAL MRI. *Neuro-Oncology*, **2020**, 22, ii157-ii157   1

175   The Role of Radionuclide Diagnostic Methods in Neuro-Oncology. *Vestnik Rentgenologii I Radiologii*, **2020**, 101, 221-234   0.3

174   Metabolic Imaging of Brain Metastasis **2020**, 159-171

173   FET and FDOPA PET Imaging in Glioma **2020**, 211-221   1

172   Feature-based PET/MRI radiomics in patients with brain tumors. *Neuro-Oncology Advances*, **2020**, 2, iv15-iv21   4

171   Combined FET PET/ADC mapping: improved imaging of glioma infiltration?. *Neuro-Oncology*, **2020**, 22, 313-314   1

170   Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. *Expert Review of Neurotherapeutics*, **2020**, 20, 137-146   4.3   1

169   Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. *Expert Review of Anticancer Therapy*, **2020**, 20, 9-15   3.5   7

168   A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. *Cancers*, **2020**, 12,   6.6   11

167   Reply: Flare Phenomenon in -(2-[F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas. *Journal of Nuclear Medicine*, **2020**, 61, 1852   8.9   1

166   FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. *Cancers*, **2020**, 12,   6.6   26

165   Comparison of [F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study. *Molecular Imaging and Biology*, **2020**, 22, 198-207   3.8   6

164   F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience. *Journal of Nuclear Medicine*, **2020**, 61, 505-511   8.9   22

163   Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. *Neuro-Oncology*, **2020**, 22, 17-30   1   43

162   Effect of Zolpidem in the Aftermath of Traumatic Brain Injury: An MEG Study. *Case Reports in Neurological Medicine*, **2020**, 2020, 8597062   0.7   4

161   Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 1444-1453   21.7   16

160	Comment on "Hypometabolic gliomas on FET-PET-is there an inverted U-curve for survival?". *Neuro-Oncology*, **2019**, 21, 1612-1613	1	5
159	Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients. *Cancers*, **2019**, 11,	6.6	23
158	Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1889-1901	8.8	28
157	Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. *Neuro-Oncology*, **2019**, 21, 1331-1338	1	19
156	Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma. *Radiation Oncology*, **2019**, 14, 73	4.2	20
155	Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma. *World Neurosurgery*, **2019**, 127, 213-215	2.1	3
154	Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma. *Frontiers in Oncology*, **2019**, 9, 84	5.3	11
153	Treatment-Related Uptake of -(2-F-Fluoroethyl)-l-Tyrosine and l-[Methyl-H]-Methionine After Tumor Resection in Rat Glioma Models. *Journal of Nuclear Medicine*, **2019**, 60, 1373-1379	8.9	4
152	Influence of Dexamethasone on O-(2-[F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake. *Molecular Imaging and Biology*, **2019**, 21, 168-174	3.8	8
151	Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. *British Journal of Neurosurgery*, **2019**, 1-7	1	7
150	Current status of PET imaging in neuro-oncology. *Neuro-Oncology Advances*, **2019**, 1, vdz010	0.9	51
149	Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. *Journal of Neuro-Oncology*, **2019**, 144, 501-509	4.8	1
148	Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. *Neuro-Oncology Advances*, **2019**, 1, vdz038	0.9	6
147	Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. *Journal of Clinical Oncology*, **2019**, 37, e13525-e13525	2.2	2
146	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet, The*, **2019**, 393, 678-688	40	207
145	NIMG-05. THE T2-FLAIR MISMATCH SIGN IN IDH-MUTANT ASTROCYTOMAS - IS THERE AN ASSOCIATION WITH FET PET UPTAKE?. *Neuro-Oncology*, **2019**, 21, vi162-vi162	1	1
144	NIMG-46. IMPACT OF FET PET ON MULTIDISCIPLINARY NEUROONCOLOGICAL TUMOR BOARD DECISIONS IN PATIENTS WITH BRAIN TUMORS. *Neuro-Oncology*, **2019**, 21, vi171-vi172	1	78
143	Dynamic FET PET Imaging of a "Butterfly" IDH-Wildtype Anaplastic Astrocytoma. *Clinical Nuclear Medicine*, **2019**, 44, e581-e582	1.7	1

142	Cis-4-[18F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism. *Nuclear Medicine Communications*, **2019**, 40, 383-387	1.6	1
141	Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[F]fluoroethyl)-L-tyrosine PET. *Clinical Lung Cancer*, **2019**, 20, e148-e151	4.9	7
140	PET imaging in patients with brain metastasis-report of the RANO/PET group. *Neuro-Oncology*, **2019**, 21, 585-595	1	72
139	FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 591-602	8.8	34
138	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 540-557	8.8	198
137	Clinical routine assessment of palliative care symptoms and concerns and caregiver burden in glioblastoma patients: an explorative field study. *Journal of Neuro-Oncology*, **2018**, 138, 321-333	4.8	9
136	Investigation of cis-4-[F]Fluoro-D-Proline Uptake in Human Brain Tumors After Multimodal Treatment. *Molecular Imaging and Biology*, **2018**, 20, 1035-1043	3.8	4
135	Comparison of O-(2-F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study. *World Neurosurgery*, **2018**, 113, e727-e737	2.1	21
134	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1626-1635	8.8	12
133	Spatial Relationship of Glioma Volume Derived from F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study. *Journal of Nuclear Medicine*, **2018**, 59, 603-609	8.9	19
132	The Treatment of Gliomas in Adulthood. *Deutsches A&#x0308;rzteblatt International*, **2018**, 115, 356-364	2.5	15
131	Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 2377-2386	8.8	31
130	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	20
129	Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. *NeuroImage: Clinical*, **2018**, 20, 537-542	5.3	79
128	Investigational PET tracers for high-grade gliomas. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 62, 281-294	1.4	5
127	Survival effects of a strategy favoring second-line multimodal treatment compared to supportive care in glioblastoma patients at first progression. *Journal of Neurosurgery*, **2018**, 1-6	3.2	
126	Static and dynamic F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 443-451	8.8	73
125	Evaluation of factors influencing F-FET uptake in the brain. *NeuroImage: Clinical*, **2018**, 17, 491-497	5.3	13

106	O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. *Neuro-Oncology*, **2017**, 19, 1271-1278	1	16
105	AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells. *Clinical Nuclear Medicine*, **2017**, 42, e506-e508	1.7	8
104	O-(2-[F]fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres. *EJNMMI Research*, **2017**, 7, 64	3.6	11
103	Comparison of F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 2257-2265	8.8	41
102	Pseudoprogression after glioma therapy: an update. *Expert Review of Neurotherapeutics*, **2017**, 17, 1109-1115	4.3	32
101	Rezidivdiagnostik bei Hirntumoren **2017**, 32, 312-316	0.2	
100	Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase F-FET PET accuracy without dynamic scans. *European Radiology*, **2017**, 27, 2916-2927	8	62
99	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. *Journal of Nuclear Medicine*, **2017**, 58, 129-137	8.9	34
98	Influence of blood-brain barrier permeability on O-(2-F-fluoroethyl)-L-tyrosine uptake in rat gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 408-416	8.8	18
97	NIMG-32. DIFFERENTIATION OF PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS BASED ON FET PET RADIOMICS. *Neuro-Oncology*, **2017**, 19, vi148-vi149	1	3
96	F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. *Journal of Nuclear Medicine*, **2017**, 58, 584-589	8.9	29
95	Positron-Emission-Tomography in Diffuse Low-Grade Gliomas **2017**, 263-286		2
94	The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. *Neuro-Oncology*, **2017**, 19, 710-718	1	6
93	Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury. *Neuro-Oncology*, **2017**, 19, 300-301	1	
92	Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. *Neuro-Oncology*, **2017**, 19, 281-288	1	69
91	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. *Neuro-Oncology*, **2016**, 18, 744-51	1	46
90	Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1115-23	8.8	15
89	Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. *Clinical Cancer Research*, **2016**, 22, 2190-6	12.9	78

88	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. *Oncotarget*, **2016**, 7, 82028-82045	3.3	15
87	Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?. *Frontiers in Neurology*, **2016**, 7, 120	4.1	32
86	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *Neuro-Oncology*, **2016**, 18, 1529-1537	1	80
85	Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. *Radiation Oncology*, **2016**, 11, 87	4.2	22
84	Letter to the Editor: "Comparing the Volume of Brain Metastases in F-18-FET-PET and MRI". *World Neurosurgery*, **2016**, 89, 722	2.1	1
83	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro-Oncology*, **2016**, 18, 1199-208	1	398
82	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. *Neuro-Oncology*, **2016**, 18, 1462-4	1	52
81	Suspected new-onset autoimmune temporal lobe epilepsy with amygdala enlargement. *Epilepsia*, **2016**, 57, 1485-94	6.4	33
80	Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 459-67	8.8	18
79	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 685-95	8.8	164
78	From the clinician○ point of view - What is the status quo of positron emission tomography in patients with brain tumors?. *Neuro-Oncology*, **2015**, 17, 1434-44	1	116
77	Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 905-15	8.8	45
76	Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. *European Radiology*, **2015**, 25, 3017-24	8	65
75	The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. *Journal of Nuclear Medicine*, **2015**, 56, 88-92	8.9	47
74	The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. *Neuro-Oncology*, **2015**, 17, 1293-300	1	100
73	Pitfalls in der [18F]-FET-PET-Diagnostik von Hirntumoren. *Chinese Journal of Polymer Science (English Edition)*, **2015**, 38, 295-303	0.1	2
72	Coma and cerebral imaging. *SpringerPlus*, **2015**, 4, 180		3
71	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. *Journal of Clinical Oncology*, **2015**, 33, 2001-2001	2.2	7

70	Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases. *Journal of Neuro-Oncology*, **2014**, 120, 615-23	4.8	29
69	Adapting MR-BrainPET scans for comparison with conventional PET: experiences with dynamic FET-PET in brain tumours. *EJNMMI Physics*, **2014**, 1, A64	4.4	
68	Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. *Journal of Nuclear Medicine*, **2014**, 55, 540-5	8.9	91
67	Histogram analysis reveals a better delineation of tumor volume from background in 18F-FET PET compared to CBV maps in a hybrid PET-MR studie in gliomas. *Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment*, **2014**, 734, 175-178	1.2	2
66	Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. *Journal of Neuro-Oncology*, **2014**, 120, 665-6	4.8	15
65	Reply: discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions. *Journal of Nuclear Medicine*, **2014**, 55, 176	8.9	1
64	Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. *Nuclear Medicine Communications*, **2014**, 35, 245-51	1.6	17
63	Isomers of 4-[18F]fluoro-proline: radiosynthesis, biological evaluation and results in humans using PET. *Current Radiopharmaceuticals*, **2014**, 7, 123-32	1.8	9
62	Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. *Radiation Oncology*, **2013**, 8, 52	4.2	41
61	"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. *Journal of Neuro-Oncology*, **2013**, 112, 209-15	4.8	10
60	Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 22-33	8.8	136
59	Detection of remote neuronal reactions in the Thalamus and Hippocampus induced by rat glioma using the PET tracer cis-4-[F]fluoro-D-proline. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 724-31	7.3	8
58	Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. *Journal of Nuclear Medicine*, **2013**, 54, 229-35	8.9	134
57	Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. *Journal of Neurology*, **2013**, 260, 1367-74	5.5	36
56	Sensitivity of intraoperative 5-aminolevulinic acid fluorescence compared with PET using O-(2-F-fluoroethyl)-L-tyrosine to detect cerebral gliomas. *Neurological Research*, **2013**, 35, 329-30	2.7	
55	Clinical value of 2-deoxy-[18F]fluoro-D-glucose positron emission tomography in patients with cervical spondylotic myelopathy. *Neurosurgical Focus*, **2013**, 35, E2	4.2	6
54	Hypermetabolism in 18F-FDG PET predicts favorable outcome following decompressive surgery in patients with degenerative cervical myelopathy. *Journal of Nuclear Medicine*, **2013**, 54, 1577-83	8.9	15
53	5-Aminolevulinic Acid and (18)F-FET-PET as Metabolic Imaging Tools for Surgery of a Recurrent Skull Base Meningioma. *Journal of Neurological Surgery, Part B: Skull Base*, **2013**, 74, 211-6	1.5	28

52	Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region. *Neuro-Oncology*, **2013**, 15, 1721-31	1	19
51	Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al. *Neuro-Oncology*, **2013**, 15, 816-7	1	12
50	The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. *Journal of Nuclear Medicine*, **2013**, 54, 1217-22	8.9	38
49	Clinical value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma. *Neurosurgical Focus*, **2013**, 34, E3	4.2	20
48	PET Imaging of Brain Tumors. *Medical Radiology*, **2013**, 121-134	0.2	1
47	Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. *Journal of Nuclear Medicine*, **2013**, 54, 2046-54	8.9	94
46	Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful?. *Molecular Imaging*, **2013**, 12, 7290.2013.00056	3.7	13
45	Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-18F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging. *Molecular Imaging*, **2013**, 12, 7290.2013.00051	3.7	33
44	Positron Emission Tomography in Diffuse Low-Grade Gliomas **2013**, 235-248		
43	Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluorethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. *Molecular Imaging*, **2013**, 12, 273-6	3.7	17
42	Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-[F]fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?. *Molecular Imaging*, **2013**, 12, 388-95	3.7	10
41	Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. *Journal of Nuclear Medicine*, **2012**, 53, 1367-74	8.9	140
40	Volumetry of [11C]-Methionine Positron Emission Tomographic Uptake as a Prognostic Marker before Treatment of Patients with Malignant Glioma. *Molecular Imaging*, **2012**, 11, 7290.2012.00022	3.7	24
39	11C-Methionine Positron Emission Tomographic Imaging of Biologic Activity of a Recurrent Glioblastoma Treated with Stereotaxy-Guided Laser-Induced Interstitial Thermotherapy. *Molecular Imaging*, **2012**, 11, 7290.2011.00046	3.7	11
38	Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. *Strahlentherapie Und Onkologie*, **2012**, 188, 334-9	4.3	91
37	Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. *Journal of Nuclear Medicine*, **2012**, 53, 1048-57	8.9	156
36	The severity of ischemia determines and predicts malignant brain edema in patients with large middle cerebral artery infarction. *Cerebrovascular Diseases*, **2012**, 33, 1-7	3.2	30
35	Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure. *Case Reports in Oncology*, **2012**, 5, 490-4	1	11

34	11C-Methionine positron emission tomographic imaging of biologic activity of a recurrent glioblastoma treated with stereotaxy-guided laser-induced interstitial thermotherapy. *Molecular Imaging*, **2012**, 11, 265-71	3.7	8
33	Volumetry of [11C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. *Molecular Imaging*, **2012**, 11, 516-27	3.7	24
32	Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. *Radiotherapy and Oncology*, **2011**, 99, 218-24	5.3	71
31	Imaging of Non or Very Subtle Contrast-Enhancing Malignant Gliomas with [11C]-Methionine Positron Emission Tomography. *Molecular Imaging*, **2011**, 10, 7290.2011.00014	3.7	22
30	[18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. *Molecular Imaging and Biology*, **2011**, 13, 547-557	3.8	20
29	Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. *European Neurology*, **2011**, 66, 183-9	2.1	23
28	Prognostic value of 18F-FDG PET in monosegmental stenosis and myelopathy of the cervical spinal cord. *Journal of Nuclear Medicine*, **2011**, 52, 1385-91	8.9	23
27	Thoracic disc herniation with affection of the anterior spinothalamic tract: a case report and review of literature. *Neurology India*, **2011**, 59, 627-8	0.7	1
26	Imaging of non- or very subtle contrast-enhancing malignant gliomas with [11C]-methionine positron emission tomography. *Molecular Imaging*, **2011**, 10, 453-9	3.7	13
25	Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma. *Molecular Imaging*, **2010**, 9, 7290.2010.00002	3.7	40
24	Systemic thrombolysis with rt-PA in patients under 40 years of age: a subgroup analysis of the Cologne Stroke Experience. *Cerebrovascular Diseases*, **2010**, 30, 514-8	3.2	8
23	Interesting image. PET imaging of a butterfly glioblastoma. *Clinical Nuclear Medicine*, **2010**, 35, 49-50	1.7	7
22	Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide. *Clinical Neuropharmacology*, **2010**, 33, 216-7	1.4	10
21	Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 84-92	8.8	77
20	Traction lesion of the brachial plexus during bodyflying. *Journal of Neurology*, **2010**, 257, 851-2	5.5	1
19	Sequential escalation of therapy in "malignant" cerebral venous and sinus thrombosis. *Neurocritical Care*, **2010**, 12, 98-102	3.3	13
18	A giant bilateral calcified chronic subdural hematoma. *Neurocritical Care*, **2010**, 12, 272-3	3.3	10
17	[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. *Journal of Neuro-Oncology*, **2010**, 96, 231-9	4.8	59

#	Publication	IF	Cit.
16	Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. *Molecular Imaging*, **2010**, 9, 40-6	3.7	20
15	Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. *Journal of Neuro-Oncology*, **2009**, 93, 425-30	4.8	13
14	Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit. *Neurocritical Care*, **2009**, 11, 317-21	3.3	18
13	Diagnostic value of the electromyography of the extraocular muscles. *Clinical Neurophysiology*, **2008**, 119, 2785-8	4.3	1
12	Ocular flutter, generalized myoclonus, and trunk ataxia associated with anti-GQ1b antibodies. *Archives of Neurology*, **2008**, 65, 659-61		26
11	11C-flumazenil positron emission tomography demonstrates reduction of both global and local cerebral benzodiazepine receptor binding in a patient with Stiff Person Syndrome. *Journal of Neurology*, **2008**, 255, 1361-4	5.5	11
10	Rapid geographical clustering of wound botulism in Germany after subcutaneous and intramuscular injection of heroin. *Neurocritical Care*, **2007**, 6, 30-4	3.3	14
9	Early electroencephalography in acute ischemic stroke: prediction of a malignant course?. *Clinical Neurology and Neurosurgery*, **2007**, 109, 45-9	2	43
8	Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 516-24	8.8	116
7	Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. *Journal of Neuroscience*, **2006**, 26, 1343-54	6.6	219
6	A rare differential diagnosis in dysphagia: wound botulism. *Laryngoscope*, **2006**, 116, 831-2	3.6	8
5	Deep brain stimulation of the subthalamic nucleus reversibly deteriorates stuttering in advanced Parkinson's disease. *Journal of Neural Transmission*, **2006**, 113, 625-31	4.3	40
4	Multitracer PET imaging in Heidenhain variant of Creutzfeldt-Jakob disease. *Journal of Neurology*, **2006**, 253, 258-60	5.5	10
3	18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. *Journal of Nuclear Medicine*, **2005**, 46, 1948-58	8.9	171
2	Role for neuronal insulin resistance in neurodegenerative diseases. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 3100-5	11.5	499
1	Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. *Human Gene Therapy*, **2003**, 14, 277-97	4.8	61